Jazwinski Alison B, Muir Andrew J
Dr. Jazwinski is a Fellow and Dr. Muir is an Associate Professor in the Division of Gastroenterology and Duke Clinical Research Institute at Duke University Medical Center in Durham, North Carolina.
Gastroenterol Hepatol (N Y). 2011 Mar;7(3):154-62.
Treatment of hepatitis C virus has traditionally been difficult because of low rates of treatment success and high rates of treatment discontinuation due to side effects. Current standard therapy consists of pegylated interferon α and ribavirin, both of which have nonspecific and largely unknown mechanisms of action. New therapies are in development that act directly on the hepatitis C virus at various points in the viral life cycle. Published clinical trial data on these therapies are summarized in this paper. A new era of hepatitis C virus treatment is beginning, the ultimate goals of which will be directly targeting the virus, shortening the length of therapy, improving sustained virologic response rates, and minimizing side effects.
传统上，丙型肝炎病毒的治疗一直很困难，原因在于治疗成功率低，且因副作用导致治疗中断率高。目前的标准疗法包括聚乙二醇化干扰素α和利巴韦林，二者的作用机制均是非特异性的，且在很大程度上尚不明确。正在研发的新疗法可在病毒生命周期的不同阶段直接作用于丙型肝炎病毒。本文总结了关于这些疗法已发表的临床试验数据。丙型肝炎病毒治疗的新时代即将开启，其最终目标将是直接靶向病毒、缩短治疗疗程、提高持续病毒学应答率并将副作用降至最低。
